A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Following this FDA approval for the phase 1 clinical trial, the NRI's innovative preclinical work was translated into the clinic with the first patient treated on September 9, 2024. This ...

A new Phase 1 clinical trial at Mass General Brigham is testing a groundbreaking Parkinson’s treatment. It uses a patient’s own stem cells to replace damaged dopamine cells in the brain.